NCT04535713
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04535713
Title Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Oncology Research Center, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field